Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?-Reference-Cited by-同舟云学术

Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?

Published:2021-02-23 Issue:8 Volume:143 Page:780-782
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Cheng Alice Y.Y.¹^ORCID

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Medicine, Trillium Health Partners and Unity Health Toronto, University of Toronto, Canada.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Standards of medical care in diabetes: 2021.;American Diabetes Association;Diabetes Care,2020

2. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada.;Diabetes Canada Clinical Practice Guidelines Expert Committee;Can J Diabetes,2018

3. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

4. Association of SGLT inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis [published online October 7, 2020].;McGuire DK;JAMA Cardiol

5. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis;Cardiovascular Diabetology;2024-08-31

2. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial;The Lancet;2024-08

3. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13

4. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity;Cardiovascular Research;2023-12

5. Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes;Diabetology;2023-09-07